Radiation therapy company Accuray Inc. (ARAY) announced Wednesday that the Chinese National Medical Products Administration or NMPA has approved the registration dossier for the Accuray Precision Treatment Planning System or TPS.The Accuray Precision TPS is now available for use with the CNNC-Accuray joint venture Tomo C radiation therapy system.

放射治疗公司Accuray Inc.（ARAY）周三宣布，中国国家医疗产品管理局（NMPA）已批准Accuray精准治疗计划系统（TPS）的注册档案。Accuray Precision TPS现在可与CNNC Accuray合资公司Tomo C放射治疗系统一起使用。

It will provide medical care teams with a new option for delivering extremely precise and accurate radiotherapy treatments.The company noted that the system was developed to facilitate the creation and adaptation of precise treatment plans in less time..

它将为医疗团队提供一种新的选择，以提供极其精确和准确的放射治疗。该公司指出，该系统的开发旨在促进在更短的时间内创建和调整精确的治疗计划。。

Suzanne Winter, president and CEO of Accuray, said, 'We couldn't be more pleased about the approval of the Accuray Precision Treatment Planning System and the potential it represents, in combination with the Tomo C System, for cancer patients in China, a country which accounted for approximately 25 percent of new cancer cases diagnosed worldwide in 20201.

Accuray总裁兼首席执行官苏珊娜·温特（SuzanneWinter）表示，“我们对Accuray精准治疗计划系统的批准以及它与Tomo C系统相结合对中国癌症患者的潜力感到非常高兴，中国在20201年约占全球新诊断癌症病例的25%。

With this approval our China joint venture can begin shipping the Tomo C System to their end customers, an important step forward in helping to address an unmet need for precision radiation therapy.'For More Such Health News, visit rttnews.com For comments and feedback contact: editorial@rttnews.comBusiness News.

有了这一批准，我们的中国合资企业可以开始向其最终客户运送Tomo C系统，这是帮助解决未满足的精确放射治疗需求的重要一步。”有关更多此类健康新闻，请访问rttnews.com获取评论和反馈联系方式：editorial@rttnews.comBusiness新闻。

Biotech Stocks Facing FDA Decision In June 2024

2024年6月美国食品和药物管理局（FDA）决定生物技术股

Biotech Stocks Facing FDA Decision In April 2024

2024年4月美国食品和药物管理局（FDA）决定生物技术股

Biotech Stocks Facing FDA Decision in March 2024

2024年3月美国食品和药物管理局决定生物技术股